Safety, Tolerability, and Pharmacokinetics of Two Dose Strengths of a Single Subcutaneous Dose of BI 655130 and One Single Intravenous Dose of BI 655130 in Healthy Male and Female Subjects (Open-label, Parallel Group Design)
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Spesolimab (Primary) ; Spesolimab (Primary)
- Indications Pustular psoriasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 01 Dec 2022 Results from Phase I Clinical Studies ( NCT02525679, NCT02852824, NCT03100903, NCT03123094, NCT03617835 ) assessing pharmacokinetics of spesolimab and evaluate changes with respect to dose, frequency of dosing, formulation and injection site. Immunogenicity, safety and tolerability published in the Clinical Pharmacokinetics
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 29 Dec 2017 to 10 Jan 2018.